Tanabe Pharma
Creating hope for all facing illness.

Press Release

November 19, 2026

Tanabe Pharma Announces Wind-Down of Operations at Its Wholly Owned Subsidiary NeuroDerm Ltd.

Tanabe Pharma Corporation (Head Office: Osaka, Japan; Representative Director, CEO: Akihisa Harada; hereinafter “Tanabe Pharma”) announced today that it has decided to wind down the operations of its wholly owned subsidiary, NeuroDerm Ltd. (Head Office: Rehovot, Israel; hereinafter, "NeuroDerm").

NeuroDerm is an Israel-based pharmaceutical company with strengths in formulation research for central nervous system therapies and in the development of drug-device combination technologies. Tanabe Pharma acquired NeuroDerm as a wholly owned subsidiary in October 2017.

The decision follows a comprehensive review of Tanabe Pharma’s future business strategy, business portfolio optimization, and strategic allocation of management resources. The wind-down will be carried out in accordance with applicable local laws and regulations.

Tanabe Pharma has positioned the Japanese market as the core driver of its future growth. By focusing management resources on priority therapeutic areas and new growth opportunities, the company aims to further strengthen its business foundation.

About Tanabe Pharma
Tanabe Pharma Corporation is a Japan-focused, innovation-driven pharmaceutical company guided by its mission, "Creating hope for all facing illness." Founded in 1678, the company is one of Japan's oldest pharmaceutical companies and is committed to addressing unmet medical needs through R&D, business development, and strategic partnerships with the aim of improving the lives of patients.
For more information, visit https://www.tanabe-pharma.com/en/